Literature DB >> 30605888

In vitro and in silico evaluation of new thiazole compounds as monoamine oxidase inhibitors.

Begüm Nurpelin Sağlık1, Betül Kaya Çavuşoğlu2, Derya Osmaniye3, Serkan Levent3, Ulviye Acar Çevik3, Sinem Ilgın4, Yusuf Özkay3, Zafer Asım Kaplancıklı2, Yusuf Öztürk5.   

Abstract

New twenty compounds bearing thiazole ring (3a-3t) were designed and synthesized as monoamine oxidase (MAO) inhibitors. The fluorometric enzyme inhibition assay was used to determine the biological effects of synthesized compounds. Most of them showed remarkable inhibitory activity against both MAO-A and MAO-B. By comparing their IC50 values, it can be seen that active derivatives displayed generally selectivity on MAO-B enzyme. Compounds 3j and 3t, which bear dihydroxy moiety at the 3rd and 4th position of phenyl ring, were the most active derivatives in the series against both isoenzymes. Compounds 3j and 3t showed significant inhibition profile on MAO-A with the IC50 values of 0.134 ± 0.004 µM and 0.123 ± 0.005 µM, respectively, while they performed selectivity against MAO-B with the IC50 values of 0.027 ± 0.001 µM and 0.025 ± 0.001 µM, respectively. Also, docking studies about these compounds were carried out to evaluate their binding modes on the active regions of MAO-A and MAO-B.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Enzyme inhibitor activity; MAO inhibitors; Molecular docking; Thiazole derivatives

Mesh:

Substances:

Year:  2018        PMID: 30605888     DOI: 10.1016/j.bioorg.2018.12.019

Source DB:  PubMed          Journal:  Bioorg Chem        ISSN: 0045-2068            Impact factor:   5.275


  5 in total

1.  Novel Thiosemicarbazone Derivatives: In Vitro and In Silico Evaluation as Potential MAO-B Inhibitors.

Authors:  Derya Osmaniye; Berkant Kurban; Begüm Nurpelin Sağlık; Serkan Levent; Yusuf Özkay; Zafer Asım Kaplancıklı
Journal:  Molecules       Date:  2021-11-02       Impact factor: 4.411

2.  Synthesis of novel benzothiazole derivatives and investigation of their enzyme inhibitory effects against Alzheimer's disease.

Authors:  Şevval Karaca; Derya Osmaniye; Begum Nurpelin Sağlık; Serkan Levent; Sinem Ilgın; Yusuf Özkay; Ahmet Çağrı Karaburun; Zafer Asım Kaplancıklı; Nalan Gundogdu-Karaburun
Journal:  RSC Adv       Date:  2022-08-19       Impact factor: 4.036

3.  Novel 1,3,4-thiadiazole compounds as potential MAO-A inhibitors - design, synthesis, biological evaluation and molecular modelling.

Authors:  Begüm Nurpelin Sağlık; Betül Kaya Çavuşoğlu; Ulviye Acar Çevik; Derya Osmaniye; Serkan Levent; Yusuf Özkay; Zafer Asım Kaplancıklı
Journal:  RSC Med Chem       Date:  2020-08-18

4.  New anti-viral drugs for the treatment of COVID-19 instead of favipiravir.

Authors:  Ahmet Aktaş; Burak Tüzün; Rukiye Aslan; Koray Sayin; Hilmi Ataseven
Journal:  J Biomol Struct Dyn       Date:  2020-08-12

5.  Design, Synthesis, In Vitro and In Silico Studies of New Thiazolylhydrazine-Piperazine Derivatives as Selective MAO-A Inhibitors.

Authors:  Begüm Nurpelin Sağlık; Osman Cebeci; Ulviye Acar Çevik; Derya Osmaniye; Serkan Levent; Betül Kaya Çavuşoğlu; Sinem Ilgın; Yusuf Özkay; Zafer Asım Kaplancıklı
Journal:  Molecules       Date:  2020-09-22       Impact factor: 4.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.